CD82 and ovarian cancer: Using human ovarian cancer cell lines (ES2 and SKOV3) and clinical samples from ovarian cancer patients, (J. Li et al., 2020) demonstrated that glycosylation of KAI1 at a specific residue (Asn 157) is a crucial post-translational modification essential for inhibition of ovarian cancer metastasis by KAI1.